Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

It met the primary outcomes. That was the trial design, to further understanding of K MOA.

“In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to evaluate the pharmacokinetics of Kevetrin when administered to subjects with platinum-resistant/refractory ovarian cancer.”

And,

“Primary Outcome Measures :
Incidence of Treatment-Emergent Adverse Events [ Time Frame: 6 Weeks ]
Reporting of Adverse Events, and severity of adverse events

Evaluate changes in biomarkers between pre-treatment sample and post-treatment sample [ Time Frame: 3 Weeks ]
Changes in RNA and/or protein level of pre-specified biomarkers associated with the p53 signalling pathway and apoptosis will be compared between pre-treatment sample (tumor biopsy, ascites fluid, and peripheral blood) and post-treatment sample (tumor biopsy, ascites fluid, and peripheral blood)”
https://clinicaltrials.gov/ct2/show/NCT03042702?cond=Ovarian+cancer+Kevetrin&rank=1

They met primary outcomes and will now work on an oral formulation before continuing with a new Phase 2 following a bridge study.